Edition:
United States

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

2.65USD
3:34pm EST
Change (% chg)

-- (+0.00%)
Prev Close
$2.65
Open
$2.60
Day's High
$2.65
Day's Low
$2.50
Volume
32,530
Avg. Vol
95,604
52-wk High
$10.15
52-wk Low
$2.15

RGLS.OQ

Chart for RGLS.OQ

About

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return... (more)

Overall

Beta: 1.93
Market Cap(Mil.): $140.25
Shares Outstanding(Mil.): 52.92
Dividend: --
Yield (%): --

Financials

  RGLS.OQ Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -1.31 -- --
ROI: -59.58 -0.59 15.23
ROE: -69.55 -1.31 16.56

BRIEF-Regulus reports third quarter 2016 financial results

* Regulus reports third quarter 2016 financial results Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Regulus Therapeutics q2 loss per share $0.40

* On track to deliver follow-up results from rg-101 studies while working to address deficiencies outlined in by fda

Aug 02 2016

FDA places Regulus' Hep C drug on clinical hold; shares dive

Regulus Therapeutics Inc said the U.S. Food and Drug Administration placed on clinical hold the company's drug to treat chronic hepatitis C virus infection, sending its shares plunging 60 percent in extended trading.

Jun 27 2016

FDA places Regulus' Hep C drug on clinical hold; shares dive

June 27 Regulus Therapeutics Inc said the U.S. Food and Drug Administration placed on clinical hold the company's drug to treat chronic hepatitis C virus infection, sending its shares plunging 60 percent in extended trading.

Jun 27 2016

BRIEF-Regulus secures $30 mln growth capital credit facility

* Says has entered into a $30 million loan and security agreement with Oxford Finance Llc

Jun 20 2016

Competitors

Earnings vs. Estimates